# Dajian Cai

> Dajian Cai is a Series B investor at ShenZhen GTJA Investment Group backing Biopharma. See 1 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [ShenZhen GTJA Investment Group](https://shizune.co/investors/profile/shenzhen-gtja-investment-group)
- Location: Shenzhen, China
- Total investments: 1
- Last investment: Aug 2017
- Lead investor: 100%
- Last updated: Aug 2026

Dajian Cai is a Series B investor at ShenZhen GTJA Investment Group in Shenzhen focused on Biopharma and Health Care. Ph.D. in Finance, EMBA at China Europe International Business School Before founding GIG, Mr. Cai had 10 years' work experience in state-owned scientific research and design companies. Inspired by the speech by Deng Xiaoping during his inspection in the south in 1992, Mr. Cai resigned from his job and started his career in Shenzhen, makinghimself one of the earliest enlighteners and explorers of venture capital as a member of the renowned JUN’AN SECURITIES and later GUOTAI JUN’AN SECURITIES , and produced the most famous IPO in that time.GIG led by Mr. Cai has earned a high reputation of innovation in both business model and investment philosophy. GIG has not only taken the lead to bring forward the “thematic industry investment” mode in the industry, but also been one of the few full-stage investment institutions in the healthcare industry in China.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biopharma | 1 | 100% |
| Health Care | 1 | 100% |
| Biotechnology | 1 | 100% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Akeso Biopharma | The company has built a global level of bio-pharmaceutical research and development and industrialization platform; established for cancer, autoimmune diseases, inflammation and cardiovascular disease of the rich product line. The scale of the company's platform, hardware and software facilities, the number of new drug product lines, R &D team in the country are the same industry-leading level. Kang Fang biological has been with the international and domestic listed pharmaceutical companies to establish a cooperative relationship, the joint development of innovative antibodies to new drugs, is a strategic cooperation in the form of development of new drugs in the forerunner. | $42.5M | Series B | Aug 29, 2017 |  |

1 of 1 investments shown.

## Co-investors
- [Qianhai Fund of Funds](https://shizune.co/investors/profile/qianhai-fund-of-funds) — VC Fund, 1 deal together
- [Shenzhen Capital Group](https://shizune.co/investors/profile/shenzhen-capital-group) — VC Fund, 1 deal together
- [TriWise Capital](https://shizune.co/investors/profile/triwise-capital) — VC Fund, 1 deal together

## About ShenZhen GTJA Investment Group

VC Fund · Shenzhen, China

ShenZhen GTJA Investment Group was founded in 2001

3 contacts available at ShenZhen GTJA Investment Group.

| Name | Title | Profile |
| --- | --- | --- |
| Dajian Cai | Chairman | https://shizune.co/investors/profile/cai-dajian |
| Haijiao Wang | Deputy General Manager | https://shizune.co/investors/profile/haijiao-wang |
| Sun Jialin | Executive Partner | https://shizune.co/investors/profile/sun-jialin |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Dajian Cai invest in?

Dajian Cai invests primarily in Biopharma, Health Care and Biotechnology startups, most often at Series B stage. Most of the 1 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Dajian Cai last invest?

The most recent investment recorded for Dajian Cai closed in Aug 2017. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co